Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mivavotinib Combinations in Advanced Non-Hodgkin Lymphoma
NCT02954406Phase 1Terminated
- Sponsor
- Millennium Pharmaceuticals
- Start
- Mar 2017
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of mivavotinib in non-Hodgkin lymphoma (NHL) (6 arms), sponsored by Millennium Pharmaceuticals. Primary endpoints: Maximum Tolerated Dose and Recommended Phase 2 Dose. Started Mar 2017; status: terminated.
02
Drugs
mivavotinib
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT02954406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02954406.